1. Impact of Treatment Prior to Allogeneic Transplantation of Hematopoietic Stem Cells in Patients with Myelodysplastic Syndrome: Results of the Latin American Bone Marrow Transplant Registry.
- Author
-
Duarte FB, Moura ATG, Funke VAM, Colturato VAR, Hamerschlak N, Vilela NC, Lopes LF, de Almeida Macedo MCM, Vigorito AC, de Almeida Soares RD, Paz A, Stevenazzi M, Diaz L, Neto AEH, Bettarello G, de Gusmão BM, Salvino MA, Calixto RF, Moreira MCR, Teixeira GM, da Silva CC, Simioni AJ, and Lemes RPG
- Subjects
- Hematopoietic Stem Cells, Humans, Latin America, Registries, Retrospective Studies, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes therapy
- Abstract
It has been suggested that bridging therapy with intensive chemotherapy and/or hypomethylating agents followed by hematopoietic stem cell transplantation (HSCT) can be valuable in the treatment of patients with myelodysplastic syndromes (MDS). However, the influence of this approach on HSCT outcomes remains poorly defined. Therefore, our objective was to investigate the influence of treatment before HSCT in patients with MDS. We retrospectively analyzed data from the Latin American registry of 258 patients from 17 Latin American centers who underwent HSCT from 1988 to 2019. Our data showed that there was pre-HSCT. We detected no significant difference regarding the impact on overall survival of treated and untreated patients before HSCT. Despite these data, the type of previous treatment among treated patients showed a significant difference in overall survival. Treatment with hypomethylating agents together with pre-HSCT chemotherapy seems to result in better survival of the studied population. These data correspond to the first results obtained through cooperative work between various centers in Latin America comparing the different approaches to patients and reflecting their reality and challenges. Therefore, the selection of pretransplant bridge therapy should be analyzed and focus given primarily to those approaches that result in better survival of patients with MDS., (Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF